Letzte Aktualisierung: September 7, 2022
Vestager stops biotech deal
The EU Commission has prohibited the planned acquisition of the US biotech company Grail by Illumina. The transaction could hinder competition for a blood-based screening test for cancer, said Margrethe Vestager, the vice president in charge. She ordered Illumina to unwind the already completed $7.1 billion acquisition. The US company announced it would appeal in court.